

Piero Ruggenenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6412221/publications.pdf>

Version: 2024-02-01

61
papers

6,844
citations

126907

33
h-index

128289

60
g-index

61
all docs

61
docs citations

61
times ranked

6714
citing authors

#	ARTICLE	IF	CITATIONS
1	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	2.5	2
2	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. <i>EClinicalMedicine</i> , 2022, 43, 101240.	7.1	6
3	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. <i>Frontiers in Pharmacology</i> , 2022, 13, 842473.	3.5	6
4	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. <i>Frontiers in Immunology</i> , 2022, 13, 827146.	4.8	45
5	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804.	2.8	10
6	Glomerular hyperfiltration. <i>Nature Reviews Nephrology</i> , 2022, 18, 435-451.	9.6	60
7	MO106: Circulating Neutrophil Count is Associated with Severity of Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
8	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , 2021, 145, 137-149.	1.8	3
9	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 575-587.	4.5	6
10	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003668.	8.4	8
11	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. <i>Frontiers in Immunology</i> , 2021, 12, 711915.	4.8	2
12	Preventing microalbuminuria with benazepril, valsartan, and benazepril+valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021, 18, e1003691.	8.4	7
13	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0261113.	2.5	25
14	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. <i>Nephron</i> , 2020, 144, 195-203.	1.8	4
15	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	1.9	17
16	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 224-238.	1.9	45
17	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	8.4	42
18	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.	4.4	14

#	ARTICLE	IF	CITATIONS
19	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , 2019, 275, 145-151.	1.7	13
20	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 27-40.	11.4	24
21	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i317-i317.	0.7	2
22	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. <i>Current Opinion in Pharmacology</i> , 2017, 33, 34-40.	3.5	28
23	Dual renin-angiotensin system blockade for nephroprotection. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S43-S45.	0.5	7
24	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 682-699.	2.9	169
25	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 700-704.	2.9	150
26	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1022-1030.e4.	4.4	45
27	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	4.5	35
28	Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study. <i>American Journal of Nephrology</i> , 2015, 41, 16-27.	3.1	4
29	Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. <i>European Journal of Heart Failure</i> , 2015, 17, 468-471.	7.1	19
30	Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 382-391.	11.4	168
31	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2545-2558.	6.1	280
32	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1205-1214.	6.1	51
33	Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 417-426.	11.4	355
34	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
35	Dreaming of normoglycaemia with fewer diet restrictions. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 350-351.	11.4	1
36	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014, 124, 1715-1726.	1.4	288

#	ARTICLE	IF	CITATIONS
37	Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205507-bcr2014205507.	0.5	8
38	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet</i> , The, 2013, 382, 1485-1495.	13.7	218
39	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 19-27.	11.4	37
40	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.8	75
41	Mechanisms and Treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1917-1928.	6.1	225
42	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-7.	0.5	9
43	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2061-2068.	8.6	259
44	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2011, 58, 776-783.	2.7	86
45	Reducing Polycystic Liver Volume in ADPKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 783-789.	4.5	126
46	Sirolimus Therapy to Halt the Progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1031-1040.	6.1	157
47	Rituximab for membranous nephropathy and immune disease: less might be enough. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 76-77.	2.0	18
48	Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 404-408.	4.4	38
49	Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1973-1985.	6.1	102
50	Latest treatment strategies for membranous nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3159-3171.	1.8	18
51	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 250-251.	2.0	2
52	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell-Targeted Therapy in Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 546-554.	4.5	44
53	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. <i>Kidney International</i> , 2005, 68, 206-216.	5.2	239
54	Preventing Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2004, 351, 1941-1951.	27.0	952

#	ARTICLE	IF	CITATIONS
55	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , 2004, 364, 503-512.	13.7	155
56	Nephropathy in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2002, 346, 1145-1151.	27.0	537
57	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. <i>Kidney International</i> , 2001, 60, 1131-1140.	5.2	334
58	ACE Inhibitors to Prevent End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2832-2837.	6.1	185
59	The Role of Protein Traffic in the Progression of Renal Diseases. <i>Annual Review of Medicine</i> , 2000, 51, 315-327.	12.2	65
60	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , 1999, 354, 359-364.	13.7	800
61	The pathophysiology and management of thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , 1996, 56, 191-207.	2.2	108